Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry

J Invest Dermatol. 2012 Mar;132(3 Pt 1):726-9. doi: 10.1038/jid.2011.383. Epub 2011 Nov 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Case-Control Studies
  • Etanercept
  • Female
  • France / epidemiology
  • Herpes Zoster / epidemiology*
  • Herpes Zoster / etiology*
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / adverse effects
  • Infliximab
  • Male
  • Middle Aged
  • Prospective Studies
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Risk
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept